falsefalse

My Treatment Approach: Expert Insights Into the Management of Polycythemia Vera - Episode 7

Managing Toxicities of Hydroxyurea in Patients With PV

,

Drs John Mascarenhas and Joe Scandura review the toxicities seen with the non-specific chemotherapeutic agent hydroxyurea in patients with polycythemia vera.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Risk Assessment in Patients With Polycythemia Vera (PV)
    EP. 2: Reducing Risk of Disease Progression in Patients With PV
    EP. 3: Typical Presentation of a Patient With PV
    EP. 4: Importance of Bone Marrow Biopsy For Diagnosis of PV
    EP. 5: Reducing Risk of Thrombosis in Patients With PV
    EP. 6: Factoring Symptom Burden Into Treatment Decision-Making for Patients With PV
    Now Viewing
    EP. 7: Managing Toxicities of Hydroxyurea in Patients With PV
    EP. 8: Managing Toxicities of Ropeginterferon Alpha-2b in Patients With PV
    EP. 9: Key Trials in the Treatment of PV
    EP. 10: Treatment Approaches for High-Risk Patients With PV
    EP. 11: Influence of Driver Mutations on Response to Ropeginterferon Alpha-2b in Patients with PV
    EP. 12: Ruxolitinib in the Treatment of PV
    EP. 13: Future Perspectives in the Treatment of Polycythemia Vera

    Related Content:

    My Treatment Approach: Expert Insights Into the Management of Polycythemia VeraMyeloproliferative NeoplasmsInsightsInsights Video Series
    Early Ruxolitinib Initiation Increases Spleen Response Rates in Myelofibrosis
    Dr Vachhani on the Potential Disease-Modifying Benefits of Navtemadlin in Myelofibrosis
    Presenting the Treatment Options in EGFR-Mutant NSCLC: Weighing the Data and Incorporating the Patient Perspective
    x